Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of subcutaneous abatacept in adults with active psoriatic arthritis
2012-002798-80Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in psoriatic arthritis (PsA) comparing Abatacept SC with Placebo SC (2 arms). Primary endpoint: ACR20 response at Day 169. Started Jun 2013; status: completed.
02
Drugs
abatacept
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2012-002798-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002798-80.